louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06677125: Magnetic Mallet and Densah Bur for Crestal Sinus Left
Official title: Magnetic Mallet Versus Densah Bur for Crestal Sinus Left With Implant Placement in Maxilla (Randomized Controlled Clinical Trial)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Maxillary Sinus Left
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2024-11-06
Enrollment: 18
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background: Implant placement in the posterior maxilla is problematic procedure, not only due to inferior properties of bone but also due to loss of vertical bone height, which happens after extraction of posterior teeth. When the required additional height is few millimeters, indirect transcrestal sinus lifting is recommended. Aim: The aim of this study is to evaluate Densah bur versus Magnetic mallet in transcrestal sinus lifting procedure in edentulous molar and premolar maxillary region.


Eligibility criteria: Inclusion Criteria:

* Patient seeking replacement of missing maxillary posterior teeth by dental implant procedure.
* Residual bone height is (5-7) mm measured from crestal bone to sinus floor.
* Both genders.
* Good general health;
* Good oral hygiene.

Exclusion Criteria:

* Uncontrolled Diabetes.
* Coagulation disorders.
* Immunological disorders.
* Previous radiation of the head and neck region.
* Presence of chronic systemic diseases;
* Presence of acute or chronic sinus problems;
* Alcohol or drug abuse;
* Heavy smokers.

Primary outcomes:
measure: Change in pain socres
timeFrame: 3rd day, 1 week and 10 days
measure: change in implant stability
timeFrame: baseline and 4 months
Secondary outcomes:
measure: change in implant protrusion length
timeFrame: baseline and 4 months
measure: change in bone density
timeFrame: baseline and 4 months
measure: change in prescence of complications
timeFrame: 3rd day, 1 week and 10 days
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Alexandria Faculty of Dentistry
Study officials:
References:
Clinical trial NCT02121925: Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up
Official title: LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Lung Cancer
NSCLC
Lung Adenocarcinoma
Keywords: Registry
Lead sponsor: Myriad Genetic Laboratories, Inc.
Sponsor class: INDUSTRY
First posted: 2014-04-24
Enrollment: 227
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Recently diagnosed treatment-naïve patients with early stage NSCLC (lung adenocarcinoma)

Brief summary: This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment decisions of Surgeons when added to standard clinical-pathological parameters in patients with early stage NSCLC.The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006).This registry is specific to Surgeons (ONC003). Outcomes measures on lung cancer relapse and death from any cause will be collected.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of early stage non-small cell lung adenocarcinoma
* Sub-population staging (IA, IB or IIA) as judged by the standard of practice at the investigational site
* Resection of tumor within previous 2 months of enrollment
* ECOG performance of 0-2
* A minimum life expectancy of six months

Exclusion Criteria:

* Pre-operative radiation or chemotherapy for NSCLC
* Post-operative radiation or chemotherapy for NSCLC
* Enrollment in a separate clinical trial restricting treatment options
* Unable to provide informed consent

Primary outcomes:
measure: Percentage change from Pre-Test to Post-Test referral
timeFrame: 3 months
Secondary outcomes:
measure: Percentage change from the Pre-test referral to the 60-day Post-Test referral
timeFrame: 2 months
measure: Percentage of patients at 60 days post test receiving treatment
timeFrame: 2 months
measure: Percentage change from Pre-Test to Post-Test chest surveillance plan
timeFrame: 3 months
measure: Assessment of disease free survival from resection to relapse or death
timeFrame: 3 years
Other outcomes:
Locations:
city: Seattle
country: United States
state: Washington
Study officials:
affiliation: Myriad Genetic Laboratories, Inc.
name: Richard Wenstrup, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03808025: Opioid Use in Shoulder Arthroplasty Patients: A Stratification and Algorithm
Official title: Opioid Use in Shoulder Arthroplasty Patients: A Stratification and Algorithm
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Opioid Use
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2019-01-17
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The investigators aim to better understand opioid use in patients undergoing elective shoulder surgery. The investigators will prospectively determine actual postoperative opioid use, while evaluating whether implementation of an educational session with pain contract would help minimize opioid use.

Detailed description: The investigators aim to better understand opioid use in patients undergoing elective shoulder surgery. As part of a multi-part investigation, The investigators intend to prospectively determine actual postoperative opioid use, while evaluating whether implementation of an educational session with pain contract would help minimize opioid use. Through use of a teaching session and pain contract, it is hypothesized opioid use would decrease. The investigators hypothesize the use of a pain contract and thorough discussion regarding proper opioid use and side-effects, will decrease the amount of postoperative opioid use.

Eligibility criteria: Inclusion Criteria:

* 18 years or older with capacity to consent
* presenting to UC Davis Medical Center Department of Orthopedic Surgery and planning to undergo elective shoulder surgery

Exclusion Criteria:

* unable to consent
* prisoners
* children
* pregnant women

Primary outcomes:
measure: Opioid use
timeFrame: 6 months after surgery
Secondary outcomes:
measure: Number of refills
timeFrame: 6 months after surgery
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: UC Davis Department of Orthopaedic Surgery
state: California
Study officials:
affiliation: University of California, Davis
name: Robert M Szabo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05030922: Cardiovascular Risk Reduction-Diet in Pregnancy - Follow up 20 Years After the "CARRDIP"-Trial
Official title: Cardiovascular Risk Reduction-Diet in Pregnancy - Follow up 20 Years After the "CARRDIP"-Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Nutrition
Lead sponsor: University of Oslo
Sponsor class: OTHER
Collaborators: name: Oslo University Hospital
First posted: 2021-09-01
Enrollment: 538
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The "Cardiovascular Risk Reduction-Diet in Pregnancy" (CARRDIP) - is a randomised controlled trial with dietary intervention during pregnancy. The participants were enrolled in Norway 20 years ago and consisted of 269 pregnant, healthy mothers. The participants were randomised 1:1 to either intervention-diet or control. The intervention diet was build upon an anti-atherogenic principle and was a so called "Mediterranean diet". The participants were monitored during pregnancy, and mother and child participated in a follow-up study 1 year after birth. The current "CARRDIP20" trial is a follow-up of the same participants, both mother and offspring, 20 years after the original intervention to measure and analyse the cardiovascular health and compare the intervention group to the control group.


Eligibility criteria: Inclusion Criteria from original CARRDIP-trial:

* Non-smoking pregnant women
* BMI 19 to 32 kg/m2 at inclusion
* Age 21 to 38 years
* Carrying a single foetus

Exclusion Criteria:

* Previous pregnancy complications

Primary outcomes:
measure: Cardiovascular health score
timeFrame: 1 day
Secondary outcomes:
measure: Blood samples - Lipid profile
timeFrame: 1 day
measure: Blood samples - Lipid profile
timeFrame: 1 day
measure: Anthropometry
timeFrame: 1 day
measure: Body fat percentage
timeFrame: 1 day
measure: Ultrasound examination of liver
timeFrame: 1 day
measure: Ultrasound examination of carotid artery
timeFrame: 1 day
measure: Blood samples - Glukose metabolism
timeFrame: 1 day
measure: Mean arterial pressure (MAP)
timeFrame: 1 day
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: University of Oslo
Study officials:
References:
citation: Khoury J, Haugen G, Tonstad S, Froslie KF, Henriksen T. Effect of a cholesterol-lowering diet during pregnancy on maternal and fetal Doppler velocimetry: the CARRDIP study. Am J Obstet Gynecol. 2007 Jun;196(6):549.e1-7. doi: 10.1016/j.ajog.2007.01.017.
citation: Khoury J, Henriksen T, Christophersen B, Tonstad S. Effect of a cholesterol-lowering diet on maternal, cord, and neonatal lipids, and pregnancy outcome: a randomized clinical trial. Am J Obstet Gynecol. 2005 Oct;193(4):1292-301. doi: 10.1016/j.ajog.2005.05.016.
citation: Khoury J, Henriksen T, Seljeflot I, Morkrid L, Froslie KF, Tonstad S. Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study. BJOG. 2007 Mar;114(3):279-88. doi: 10.1111/j.1471-0528.2006.01187.x.
Clinical trial NCT01744522: Leech Therapy for Postherpetic Neuralgia
Official title: Pilot Study on the Influence of Leech Therapy on Pain and Sensory Processing in Patients With Postherpetic Neuralgia
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Postherpetic Neuralgia
Lead sponsor: Universität Duisburg-Essen
Sponsor class: OTHER
First posted: 2012-12-06
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients from an outpatient clinic for naturopathy, traditional chinese and indian medicine(secondary care)

Brief summary: The purpose of this study is to investigate, whether leech therapy for the treatment of postherpetic pain improves pain and sensory function.

Therefore 20 patients with PHN undergoing leech therapy at the investigators outpatient clinic will be included in this observational trial.

Detailed description: see above

Eligibility criteria: Inclusion Criteria:

* 18 to 85 years of age
* \>6 months thoracal postherpetic neuralgia
* informed consent

Exclusion Criteria:

* if leech therapy is contraindicated
* physical and mental disability to participate in the study examinations

Primary outcomes:
measure: Pain intensity
timeFrame: 28 days
Secondary outcomes:
measure: Pain intensity
timeFrame: 3 months
measure: Pain quality
timeFrame: 28 Days
measure: Pain quality
timeFrame: 3 months
measure: Impairment
timeFrame: 28 days
measure: Impairment
timeFrame: 3 months
measure: Quality of life
timeFrame: 28 days
measure: quality of life
timeFrame: 3 months
measure: Sensory perception and pain thresholds
timeFrame: 28 days
measure: Sensory perception and pain thresholds
timeFrame: 3 months
measure: Safety
timeFrame: 28 days
Other outcomes:
Locations:
city: Essen
country: Germany
facility: Chair of Complementary and Integrative Medicine
Study officials:
affiliation: Research fellow
name: Romy Lauche, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00343122: Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline
Official title: Evaluation of Two Methods for the Echocardiographic Assessment of Intrapulmonary Vasodilatation in Patients With Liver Cirrhosis: Agitated Saline Versus Polygelatine
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Liver
Cirrhosis
Keywords: liver
cirrhosis
hepatopulmonary syndrome
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2006-06-22
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: The purpose of the study is to evaluate agitated saline versus polygeline for detection of intrapulmonary vasodilatation in patients with cirrhosis.

Detailed description: Intrapulmonary vasodilatation is a frequent finding in patients with cirrhosis. Its diagnosis is established via contrast enhanced echocardiography. One used method is the contrast agent agitated saline and another frequently used method is the contrast agent polygeline. The purpose of this study is to compare these two echocardiographic contrast agents with respect to their ability to detect intrapulmonary vasodilatation.

Eligibility criteria: Inclusion Criteria:

* age \> 18 years
* presence of liver cirrhosis
* evaluation for liver transplantation or transjugular intrahepatic portosystemic shunt

Exclusion Criteria:

* inadequate echocardiographic image quality
* allergies to echocardiographic contrast agents
* pulmonary valve stenosis
* pulmonary embolism
* relevant tricuspid regurgitation
* cardiomyopathy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Intensive Care Unit 13H1, Dep. of Internal Medicine IV, Medical University of Vienna
Study officials:
affiliation: Intensive Care Unit 13h1, Dep. of Internal Medicine IV, Medical University of Vienna
name: Peter Schenk, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004 Nov;24(5):861-80. doi: 10.1183/09031936.04.00010904. No abstract available.
Clinical trial NCT02235922: Effects of a Dual Task Protocol on Cognition and Functionality in Non-sedentary Older Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Non-sedentary
Keywords: Aged
Exercise
Cognition
Functional capacity
Lead sponsor: Universidade Federal de Sao Carlos
Sponsor class: OTHER
First posted: 2014-09-10
Enrollment: 78
Sex: ALL
Minimum age (years): 60
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to analyze the effects of a dual task protocol on cognitive domains and functional capacity in non-sedentary older adults.

The hypothesis of the present study is that older people undergoing to a dual task exercise protocol have greater benefits on cognition and functional performance, compared to a standard exercise protocol.


Eligibility criteria: Inclusion Criteria:

* aged over 60 years
* community people
* ability to walk alone
* non-sedentary

Exclusion Criteria:

* non-realization of any cognitive or functional assessment
* presence of Parkinson's Disease, Dementia and Stroke with motor sequel
* frequency to trainings below 70%

Primary outcomes:
measure: Changes on cognition after 3 months of training
timeFrame: Assessed at baseline and after 3 months of training
measure: Changes on functional capacity after 3 months of training
timeFrame: Assessed at baseline and after 3 months of training
Secondary outcomes:
Other outcomes:
Locations:
city: São Carlos
country: Brazil
facility: Universidade Federal de São Carlos
state: São Paulo
Study officials:
affiliation: Universidade Federal de Sao Carlos
name: Anielle Takahashi, doctorate
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06009822: Investigation of Kinesiophobia and Functional Status of Patients After MPFL Reconstruction
Official title: Investigation of Kinesiophobia and Functional Status of Patients After MPFL Reconstruction
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Medial Patellofemoral Dislocation
Kinesiophobia
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2023-08-24
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent unilateral MPFL reconstruction in the Department of Orthopedics and Traumatology, Gazi University Hospital between 2004 and 2019

Brief summary: Our aim in this study is to examine the functional and clinical results of patients who have undergone MPFL reconstruction at least 2 years after the operation. The presence of kinesiophobia of the patients will be evaluated and its relationship with functional outcomes will be examined.


Eligibility criteria: Inclusion Criteria:

* Undergone unilateral medial patellofemoral ligament (MPFL) reconstruction
* At least 2 years after the operation

Exclusion Criteria:

* Patellar instability
* Knee ligament injury
* Meniscus injury
* Knee osteoarthritis
* Ankle ligament injury
* Ankle osteoarthritis
* Any neurological disease

Primary outcomes:
measure: Kinesiophobia
timeFrame: up to 3 months
Secondary outcomes:
measure: Knee Score
timeFrame: up to 3 months
measure: Patellofemoral Knee Score
timeFrame: up to 3 months
measure: Single-leg hop test
timeFrame: up to 3 months
measure: Dynamic balance
timeFrame: up to 3 months
measure: Static balance
timeFrame: up to 3 months
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University
Study officials:
affiliation: Gazi University
name: Zeynep Hazar
role: STUDY_DIRECTOR
References:
Clinical trial NCT00899522: Tissue Sample Collection From Patients With Fanconi Anemia
Official title: Fanconi Anemia Cancer Cell Repository
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fanconi Anemia
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific
Keywords: Fanconi anemia
unspecified adult solid tumor, protocol specific
unspecified childhood solid tumor, protocol specific
Lead sponsor: OHSU Knight Cancer Institute
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2009-05-12
Enrollment: 8
Sex: ALL
Minimum age (years): 1
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: To recruit participants into this project, an announcement will be posted on the Fanconi Anemia Research Fund website (http://www.fanconi.org/) after IRB approval is obtained.

Brief summary: RATIONALE: Collecting and storing samples of tumor tissue from patients with Fanconi anemia to test in the laboratory may help the study of cancer in the future.

PURPOSE: This laboratory study is collecting and storing tumor tissue samples from patients with Fanconi anemia.

Detailed description: OBJECTIVES:

* Acquire rare solid tumor samples from patients with Fanconi anemia in order to create a Fanconi Anemia Cell Repository at the Oregon Health and Science University Cancer Institute.
* Study repository tissue using a variety of molecular methods, including gene microarrays.
* Develop cancer cell lines that are publicly available from tissue archived from patients with Fanconi anemia.

OUTLINE: Tumor biopsies are collected from patients with Fanconi anemia and archived for future molecular studies, cell line generation, and general usage by the research community at large. Medical information about the patient's cancer is also archived.

PROJECTED ACCRUAL: Not specified.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Confirmed Fanconi anemia
* Confirmed malignant solid tumor
* Biopsy of tumor tissue available

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

Primary outcomes:
measure: Creation of a Fanconi Anemia Cell Repository using rare solid tumor samples from patients with Fanconi anemia
timeFrame: Duration of the study
measure: Study tissue samples by molecular methods, including gene microarrays
timeFrame: Duration of the study
measure: Development of cancer cell lines from tissue archived from patients with Fanconi anemia
timeFrame: Duration of the study
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Knight Cancer Institute at Oregon Health and Science University
state: Oregon
Study officials:
affiliation: OHSU Knight Cancer Institute
name: Grover C. Bagby, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00223522: Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?
Official title: Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Schizoaffective
Keywords: Schizophrenia
Schizoaffective
MEMS
adherence to antipsychotic medication
Lead sponsor: The University of Texas Health Science Center at San Antonio
Sponsor class: OTHER
Collaborators: name: Janssen Pharmaceutica N.V., Belgium
First posted: 2005-09-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to prospectively examine adherence to oral atypical antipsychotics in patients with schizophrenia. We are psrticularly interested in examining the level of agreement among self-report, physician impressions and objective measures of adherence. We believe that physicians, casemanagers, and clients significantly overestimate the level of adherence.

Detailed description: Fifty schizophrenia patients will be recruited at the time of their clinic visit to Tri-County MHMR Services and the El Paso Community MHMR Center. Both physicians and patients will be asked to rate the patient's medication adherence on their index clinic visit. Initial ratings will also occur at this visit. After filling their medication prescription, all subjects will be given electronic medication caps that record each time and date their medication container is opened. Patients will then be followed in the community for the next 12 weeks to observe actual adherence to medication from the index visit to the next successive clinic visit. Every two weeks pills will be counted and data will be retrieved from the electronic medication caps. During the first and last two weeks of study, blood will be sampled on two randomly selected occasions approximately 72 hours apart. Self-report and physician assessment of adherence, symptom and attitudinal measures will be obtained a second time at the second clinic visit 12 weeks after the index visit.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Schizophrenia or Schizoaffective disorder
* Between the ages of 18-55
* no documented history of head injury, mental retardation or neurological disorder

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: UTHSCSA
state: Texas
Study officials:
affiliation: University of Texas
name: Dawn I Velligan, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: